By Pushkala Aripaka, Bhanvi Satija and Maggie Fick LONDON, Feb 10 (Reuters) - AstraZeneca forecast steady profit growth in ...

AstraZeneca has reported a robust rise in revenue in 2025, driven by strong demand for its cancer medicines, and struck an ...

By Andrew Silver SHANGHAI, Jan 30 (Reuters) - AstraZeneca will license experimental drugs for obesity and weight-related conditions from CSPC Pharmaceutical Group and collaborate on other projects, ...

After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030 ...

Chinese prosecutors have brought formal charges against AstraZeneca and its former executives following investigations into alleged illegal patient data collection and importation of drugs. | Chinese ...

The pharmaceutical giant announced profit in line with expectations and revenue that slightly beat forecasts on Tuesday.

Feb 11 (Reuters) - China has officially charged AstraZeneca's former regional head, Leon Wang, who was detained by authorities in the country more than a year ago in relation to probes into the ...

Sanofi announced the signing of a share buyback mandate for up to €1 billion. Pfizer said its obesity injection, which was ...

The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive ...

Q4 2025 Earnings Call February 10, 2026 6:45 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

AstraZeneca stock rose 230p (1.64 per cent) to 14,118 per share within an hour of the London stockmarket opening this morning ...

Feb 11 (Reuters) - China has officially charged AstraZeneca's former head of the business in the country, Leon Wang, who had been in detention since October 2024, the drugmaker confirmed to Reuters on ...